Member Info for ProfessorZ

Likewise. Been here for a while now. This is a classic case of the wider market not knowing what it is sitting on, especially given how far down the line this ED product is already. The £3m market capitalisation looks very attractive indeed. The question for me is not if but when this multi-bags.

Agree with almost everything you say, but I would add that I think a Mcap of £60m for FUM is on the low side. I would also say that the means of applying the FUM treatment actually is a benefit in some cases but I would not dispute that a fast reacting ED tablet would be preferable for a high percentage of the market. I'm in both by the way.

Interesting position here. I wanted 100k shares but it went to negotiated. I managed to pick up 75k shares but the trade hasn't shown up yet. Now even 25k shares goes to negotiated. Things must be getting tight.

An excellent acquisition, a profitable entity with a clearly successful business model - we have purchased the business within a solid business model whilst it is expanding. The combination will undoubtedly compliment both operations to the benefit of future earnings. I continue to be impressed with this company, the way it operates and its growth strategy.

I absolutely agree.

So many reasons to invest today; - EU approved treatment for Premature Ejaculation - Recordati signed up to market in and around the EU - PLE have global rights to treatment - Very close to commercial sales - Regent Pacific Takeover values the company on paper at over three times the current share price. - Takeover will provide the funds to take Fortacin through the final stages and into commercial sales and take it into the US. - Regent Pacific better placed to sign further marketing agreements within the lucrative Asian market - Jim Mellon holds 30% of PLE and is behind the takeover - Current market cap <£25m in an estimated market worth over $1bn

I almost completely agree with you, but I would correct you on the point that this is the MOST undervalued. Currently that accolade goes to STG if you ignore all other investments. That being said, just over £300k per % of HHDL is still an unbelievable bargain. Remember, this is one well, the area has now been proven and the potential is absolutely enormous. In a safe part of the world, free-flowing oil 40 degree API at 1,400 bopd. Absolutely massive potential. And then there is the future.... Fracking may not be popular with some of the population, but the technology is advancing every year with the potential for some significant breakthroughs. Just look at HNR if you don't believe me. The local planning authority would actually benefit financially from fracking as it is one of the few areas where they are allowed to keep 100% of the business rates - at a time when budgets are under pressure, there will be an incentive to push forward.

I'm in until the end. But I do not rule out selling some of my holding if the share price appears to be getting ahead of itself. Once we move to RP who knows what will happen. Very excited about the next few months and particularly the European variation / 6 dose launch.

This link should explain everything to you. http://www.melroseplc.net/media/news-releases/2015/completion-of-elster-disposal-and-proposed-return-of-capital/ In short, the court hearing was required in order to return the sales proceeds to shareholders. You never received the B shares in question but it appears as though they were required for people holding Melrose in CREST accounts. You clearly hold your Melrose shares in certificate form.

I'm with you.

Interesting use of funds and on the face of it, a very good return on investment. Business is costing £7m + £3.5m depending upon Centrix's performance. A premium paid above the £613k Dec 13 net asset value, but Centrix made £2.26m profit before tax. Incorporated in 1991, no reason to suggest that this cannot be repeated. In cash terms and assuming similar profitability, the acquisition will be repay for itself in 3 to 5 years. Looks like a cracking deal to me. Well done BoD.

I agree with that. An AIM share that pays dividends, this provides a degree of stability and realism that many other AIM shares lack. It is unlikely to take-off in the same way that other shares can in this market, but the recipe for growth appears to be working well and the company seems extremely well managed. If Adept can somehow increase market share and reduce debt to zero, growth could be rapid. Given today's news, it is all heading in the right direction. The company paid the equivalent of 6.3p per share off it's net debt and a further 9.6p an acquisitions. Liquidity does not appear to be a problem at the moment. Add that to the dividend, the total cash available over the period was around 20p per share which is trading at £1.50. My only regret is that I didn't invest more in here 18 months ago. Happy to hold.

I am not entirely sure, but low volume and back up again. I do like this company, it is a shame that the spread is always so intimidating.

Good question. If you can afford 1000 shares and you have a landline contract with someone, it is worth it for just the perk. The company appears well managed and has some contracts that will keep it going. It pays a dividend and is profitable. They have been buying back shares since December - not huge amounts, but it is indicative of a company that has a degree of stability. If you are looking to trade however, I would suggest that you look elsewhere. This is definitely a long term investment. One to put in your SIPP and forget about I would say.